JP4086908B2 - 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 - Google Patents
安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 Download PDFInfo
- Publication number
- JP4086908B2 JP4086908B2 JP54433898A JP54433898A JP4086908B2 JP 4086908 B2 JP4086908 B2 JP 4086908B2 JP 54433898 A JP54433898 A JP 54433898A JP 54433898 A JP54433898 A JP 54433898A JP 4086908 B2 JP4086908 B2 JP 4086908B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- suspension
- human
- amino acid
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101001063991 Homo sapiens Leptin Proteins 0.000 title claims abstract description 56
- 102000049953 human LEP Human genes 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 title description 52
- 239000000725 suspension Substances 0.000 claims abstract description 86
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 11
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 11
- 102000016267 Leptin Human genes 0.000 claims description 47
- 108010092277 Leptin Proteins 0.000 claims description 47
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 20
- 229940039781 leptin Drugs 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 13
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 44
- 108090000623 proteins and genes Proteins 0.000 abstract description 44
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 42
- 239000000243 solution Substances 0.000 description 33
- 238000009472 formulation Methods 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 17
- 230000004580 weight loss Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 239000012460 protein solution Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108020001775 protein parts Proteins 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102400000093 Neuropeptide gamma Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 101710113414 Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 108010073085 tachykinin neuropeptide gamma Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Obesity (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84397197A | 1997-04-17 | 1997-04-17 | |
| US08/843,971 | 1997-04-17 | ||
| US09/059,467 US20020019352A1 (en) | 1997-04-17 | 1998-04-14 | Stable, active, human ob protein compositions and methods |
| US09/059,467 | 1998-04-14 | ||
| PCT/US1998/007828 WO1998046257A1 (en) | 1997-04-17 | 1998-04-16 | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007317951A Division JP4824663B2 (ja) | 1997-04-17 | 2007-12-10 | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512612A JP2002512612A (ja) | 2002-04-23 |
| JP2002512612A5 JP2002512612A5 (https=) | 2005-11-10 |
| JP4086908B2 true JP4086908B2 (ja) | 2008-05-14 |
Family
ID=26738785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54433898A Expired - Lifetime JP4086908B2 (ja) | 1997-04-17 | 1998-04-16 | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0977583B1 (https=) |
| JP (1) | JP4086908B2 (https=) |
| CN (1) | CN1202862C (https=) |
| AT (1) | ATE223229T1 (https=) |
| AU (1) | AU7132798A (https=) |
| CA (1) | CA2286098C (https=) |
| DE (1) | DE69807679T2 (https=) |
| ES (1) | ES2183351T3 (https=) |
| HU (1) | HU226175B1 (https=) |
| IL (1) | IL132380A0 (https=) |
| WO (1) | WO1998046257A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| WO1997018833A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| EP1489100B1 (en) | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| PT1783222E (pt) | 1998-10-23 | 2012-07-26 | Kirin Amgen Inc | Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2000024418A1 (en) * | 1998-10-27 | 2000-05-04 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| JP4793971B2 (ja) | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| AU5943201A (en) * | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| DE60129695T2 (de) | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| KR20030067755A (ko) * | 2001-01-18 | 2003-08-14 | 메르크 파텐트 게엠베하 | 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질 |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| PT1383785E (pt) | 2001-05-03 | 2011-06-28 | Merck Patent Gmbh | Anticorpo recombinante específico de tumores e utilização deste |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| CA2485166A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds |
| CN100432105C (zh) | 2002-12-17 | 2008-11-12 | 默克专利有限公司 | 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合 |
| CA2551915C (en) | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8642543B2 (en) | 2005-09-07 | 2014-02-04 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| EP2421896A1 (en) | 2009-04-22 | 2012-02-29 | Merck Patent GmbH | Antibody fusion proteins with modified fcrn binding sites |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| RU2650646C2 (ru) | 2012-09-27 | 2018-04-16 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Соединения, предназначенные для лечения ожирения, и способы их применения |
| SI3074033T1 (sl) | 2013-11-26 | 2019-03-29 | The Children's Medical Center Corporation | Spojine za zdravljenje debelosti in postopki njihove uporabe |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559208A (en) * | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| AU1520097A (en) * | 1995-12-27 | 1997-07-28 | Genentech Inc. | Ob protein derivatives having prolonged half-life |
| WO1998028427A1 (en) * | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
-
1998
- 1998-04-16 CN CNB988042258A patent/CN1202862C/zh not_active Expired - Fee Related
- 1998-04-16 JP JP54433898A patent/JP4086908B2/ja not_active Expired - Lifetime
- 1998-04-16 ES ES98918399T patent/ES2183351T3/es not_active Expired - Lifetime
- 1998-04-16 AU AU71327/98A patent/AU7132798A/en not_active Abandoned
- 1998-04-16 IL IL13238098A patent/IL132380A0/xx active IP Right Grant
- 1998-04-16 WO PCT/US1998/007828 patent/WO1998046257A1/en not_active Ceased
- 1998-04-16 EP EP98918399A patent/EP0977583B1/en not_active Expired - Lifetime
- 1998-04-16 HU HU0002831A patent/HU226175B1/hu not_active IP Right Cessation
- 1998-04-16 CA CA002286098A patent/CA2286098C/en not_active Expired - Fee Related
- 1998-04-16 DE DE69807679T patent/DE69807679T2/de not_active Expired - Lifetime
- 1998-04-16 AT AT98918399T patent/ATE223229T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0977583A1 (en) | 2000-02-09 |
| ES2183351T3 (es) | 2003-03-16 |
| CA2286098A1 (en) | 1998-10-22 |
| DE69807679D1 (de) | 2002-10-10 |
| HUP0002831A3 (en) | 2005-11-28 |
| WO1998046257A1 (en) | 1998-10-22 |
| IL132380A0 (en) | 2001-03-19 |
| EP0977583B1 (en) | 2002-09-04 |
| HU226175B1 (en) | 2008-06-30 |
| WO1998046257A8 (en) | 2000-01-27 |
| ATE223229T1 (de) | 2002-09-15 |
| CN1274289A (zh) | 2000-11-22 |
| HUP0002831A2 (hu) | 2000-12-28 |
| CN1202862C (zh) | 2005-05-25 |
| HK1023513A1 (en) | 2000-09-15 |
| AU7132798A (en) | 1998-11-11 |
| DE69807679T2 (de) | 2003-07-31 |
| JP2002512612A (ja) | 2002-04-23 |
| CA2286098C (en) | 2009-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4086908B2 (ja) | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 | |
| JP4824663B2 (ja) | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 | |
| JP4659068B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| US7112659B2 (en) | OB fusion protein compositions and methods | |
| JP4173913B2 (ja) | Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法 | |
| CZ266695A3 (en) | Insulintropic peptide analogs of glucane type, pharmaceutical preparation and use | |
| JP2013537525A (ja) | 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| US7208577B2 (en) | Methods of increasing lean tissue mass using OB protein compositions | |
| JP2002522512A (ja) | デキストラン−レプチン結合体、医薬組成物および関連方法 | |
| AU2002300605B8 (en) | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods | |
| HK1023513B (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
| MXPA99009384A (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
| HK1021388B (en) | Ob fusion protein compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060926 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061219 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070905 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071015 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071210 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080220 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110228 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120229 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120229 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130228 Year of fee payment: 5 |